Caribou Biosciences, Inc.

Public companies file this within four business days when something important happens that investors should know about before the next quarterly report.

Caribou Biosciences, Inc. filed this to release information to investors under Regulation FD — usually a press release, conference presentation, or other event the company considers important. 1 Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 -- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17. 1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient administration and further expansion to community centers -…